News
Several oncology companies announced key trial milestones this week across the landscape of both blood cancers and solid ...
SHELTON, CONNECTICUT / ACCESS Newswire / August 18, 2025 / NanoViricides, Inc., a publicly traded company (NYSE American:NNVC ...
More than two years after the Food and Drug Administration held a public workshop on measuring overall survival (OS) in ...
Vascular toxicity associated with cancer therapies is a leading cause of cardiovascular adverse events in patients with ...
In this episode presented by Cresset, BioSpace’s head of insights Lori Ellis discusses clinical trial fail rates and AI’s ...
Synthetic generation replicates key clinical patterns from real-world data, enabling valid analyses with fewer patients.
Private equity firm THL Partners has agreed to buy a majority stake in Headlands Research, a U.S.-based network of clinical ...
By Rishika Sadam and Bhanvi Satija (Reuters) -Japanese drugmaker Takeda Pharmaceutical is exploring the option of conducting ...
Dr. Hussein Tawbi, who works for MD Anderson in Houston, said there are two things he hopes people take away from the story ...
Dr. Miller said he was optimistic that the clinical trial results would support an F.D.A. approval, but if or when that might happen is unclear, especially given recent changes at the agency.
Results that may be inaccessible to you are currently showing.
Hide inaccessible results